NEW YORK – DarwinHealth and Prelude Therapeutics on Tuesday announced a research collaboration to identify biomarkers to guide Prelude's development of precision oncology drugs.
New York-based biotech DarwinHealth will use its Biomarker Enrichment Strategies for Trials platform to select master regulator proteins and tumor checkpoints that Prelude can use to select patients for its drug trials.
Prelude is developing two products that target PRMT5 in Phase I studies, one for advanced solid tumors and select myeloid malignancies and another for glioblastoma multiforme. The company also has additional candidates in earlier stages of development targeting MCL1, CDK9, and SMARCA2.
DarwinHealth will assess the clinical value of certain Prelude pipeline products and help design preclinical studies to validate biomarkers identified by its platform. The companies didn't disclose the financial details of their collaboration.
"The purpose of such studies is to generate a range of validated compound, tumor subtype, or biomarker alignments that represent evidence- and mechanism-based roadmaps for biomarker development and patient selection to potentially accelerate clinical studies," DarwinHealth CSO Mariano Alvarez said in a statement.